news
-
25 May 2018Wilson Therapeutics applies for Delisting
The public offer by Alexion Pharmaceuticals, Inc. through Alexion Pharma Nordics Holding AB (“Alexion”) for the shares in Wilson Therapeutics AB (publ) (“Wilson”) was declared unconditional today, 25 May 2018. Alexion owns more than 90 per cent of the shares in Wilson and intends to request compulsory acquisition in respect of the remaining shares in Wilson. The acceptance period for Alexion’s offer has been extended up to and including 8 June 2018, 3:00 p.m. CET, to allow remaining shareholders in Wilson to accept the offer.
At the request of Alexion, the Board of Directors of Wilson has resolved to apply for delisting of Wilson’s shares from Nasdaq Stockholm. The last day of trading in Wilson’s shares on Nasdaq Stockholm will be announced as soon as Wilson has received confirmation of such date from Nasdaq Stockholm.
Related
Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
WTX101 granted Fast Track designation by The U.S. FDA for the treatment of Wilson Disease
Promising preliminary long-term data for WTX101 in Wilson Disease highlighted at The Liver Meeting®
Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
Wilson Therapeutics receives US Orphan Drug Designation for WTX101 for the treatment of ALS
Wilson Therapeutics presents Phase 2 Data for WTX101 at MDS Meeting
Wilson Therapeutics presented positive Final Phase 2 Data for WTX101 at EASL Annual Meeting
Wilson Therapeutics Presents Updated Preliminary Clinical Data on WTX101 At The AASLD Liver Meeting
Wilson Therapeutics appoints Vincent Metzler as Vice President Commercial Planning & Launch Stragegy
Wilson Therapeutics appoints Rick Lilley as Chief Regulatory Officer
Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled
Wilson Therapeutics announces initial public offering on Nasdaq Stockholm
Wilson Therapeutics Appoints Andrew Kay as Chairman
Wilson Therapeutics announces the appointment of Dr. Carl Bjartmar as Chief Medical Officer
Wilson Therapeutics appoints Hans Schikan to its Board of Directors
Wilson Therapeutics announces the appointment of Dr. Carl Bjartmar as Chief Medical Officer
Wilson Therapeutics appoints Hans Schikan to its Board of Directors